Ignite Creation Date:
2024-05-06 @ 12:27 AM
Last Modification Date:
2024-10-26 @ 10:50 AM
Study NCT ID:
NCT01584466
Status:
WITHDRAWN
Last Update Posted:
2022-03-17
First Post:
2012-03-20
Brief Title:
Long Acting Paliperidone in Dually Diagnosed People With Schizophrenia An Open-label Pilot Study
Sponsor:
University of Maryland Baltimore
Organization:
University of Maryland Baltimore
Study Overview
Official Title:
Long Acting Paliperidone in Dually Diagnosed People With Schizophrenia An Open-label Pilot Study
Status:
WITHDRAWN
Status Verified Date:
2022-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Comorbid substance abuse leads to many deleterious effects such as medical comorbidities and nonadherence which is one of the most problematic issues People with schizophrenia and substance use disorders SUDs are at an increased risk nonadherence compared to those who do not use alcohol and illicit drugs The investigators propose that this new marketed injectable antipsychotic with many benefits over other available long acting injectable agents would be beneficial in the dually diagnosed population and may represent a specific schizophrenia subpopulation where long acting agents may be considered an important therapeutic option
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None